A Novel Alpha-(8-Quinolinyloxy) Monosubstituted Zinc Phthalocyanine Nanosuspension For Potential Enhanced Photodynamic Therapy

Objective To prepare alpha-(8-quinolinyloxy) monosubstituted phthalocyanine zinc nanosuspension (ZnPc-NS) for photodynamic therapy by intravenous administration. Methods The formulation and preparation technology of ZnPc-NS were assessed by particle size using the precipitation-high pressure homogenization method. The efficacy of ZnPc-NS was evaluated based on particle size, zeta potential, sedimentation ratio, TEM imaging, stability assessment, photodynamic activity and safety. Results and discussion The content, average particle size, polydispersity and photodegradation constant of ZnPc-NS were 0.2 mg/ml, 219.7 +/- 7.41 nm, 0.19 +/- 0.02 and 0.006, respectively. The photosensitization rate of singlet oxygen (O-1(2)) of the ZnPc-NS was three times higher than that of the ZnPc DMF solution. ZnPc-NS exhibited optimal antitumor activity in HepG2 cells under light exposure and low photo- and non-light-associated toxicity in HELFX cells. In addition, low hemolysis and vascular stimulation were evident in the experiments performed. Conclusion The ZnPc-NS exhibited optimal stability, faster photosensitization rate of(1)O(2), and optimal antitumor activity and safety than the ZnPc DMF solution, which could provide potential support for further research and development.